Alnylam Pharmaceuticals

Yahoo Finance • 15 hours ago

Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals

Company Logo Key opportunities in the oligonucleotide market include advancing therapeutics for rare and diverse diseases like neurodegenerative disorders and cancer, improving drug delivery systems, leveraging regulatory designations, an... Full story

Yahoo Finance • yesterday

Is Alnylam Pharmaceuticals (ALNY) The Best Growth Stock?

​Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the Best Growth Stocks to Buy With Highest Upside Potential. Wall Street has a positive view on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) as 71% of the 28 analysts covering the stock... Full story

Yahoo Finance • 4 days ago

Alnylam Pharmaceuticals (ALNY) Achieved Free Cash Flow Breakeven in 2025

ClearBridge Investments, a global equity manager, recently published first-quarter 2026 commentary for its “Large Cap Growth Strategy”. A copy of the letter can be downloaded here. Following the outbreak of the Middle East conflict, the ma... Full story

Yahoo Finance • 8 days ago

BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer

BioCryst Pharmaceuticals, Inc. — Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceu... Full story

Yahoo Finance • 8 days ago

Notable healthcare headlines for the week: Apellis, Centessa, and UnitedHealth in focus

Wall Street’s major market averages ended mixed on Thursday as markets assessed President Donald Trump’s address to the nation and the latest developments in the Middle East conflict. The tech-focused Nasdaq Composite finished +0.1%. At t... Full story

Yahoo Finance • 13 days ago

5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up

Quick Read Incyte (INCY) posted FY2025 revenue of $5.14B (+21.2% YoY) with 14 pivotal trials underway across KRASG12D and CDK2 inhibition, while Alnylam (ALNY) achieved first full-year GAAP profitability with FY2025 revenue surging 65.2%... Full story

Yahoo Finance • 13 days ago

Why Alnylam Pharmaceuticals Inc. (ALNY) is One of the Best High Growth Healthcare Stocks to Buy Now

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is one of the best high growth healthcare stocks to buy now. Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced on March 24 a set of strategic efforts aimed at accelerating earlier recognition a... Full story

Yahoo Finance • 18 days ago

Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints

Wave Life Sciences(NASDAQ:WVE), developer of RNA medicines for rare genetic diseases, closed Thursday at $6.20, down 49.59% for the session. The stock sank after disappointing higher-dose WVE-007 obesity data underperformed the lower dose.... Full story

Yahoo Finance • 19 days ago

Alnylam (ALNY) Targets 25% CAGR with Innovative Therapies

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) ranks among the best rebound stocks to buy right now. On March 2, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) outlined its growth strategy at the TD Cowen 46th Annual Health Care Conference, emph... Full story

Yahoo Finance • 19 days ago

Three Stocks Estimated To Be Priced Below Intrinsic Value In March 2026

Over the last 7 days, the United States market has experienced a 2.3% decline, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are potentially priced bel... Full story

Yahoo Finance • 28 days ago

Qualcomm, Adobe downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Clear Street upgraded Circle Internet(... Full story

Yahoo Finance • 29 days ago

Here Are Monday’s Top Wall Street Analyst Research Calls: Alnylam Pharmaceuticals, Circle Internet, Fifth Third Bancorp, Intuit, ServiceNow, Qualcomm, Trade Desk, and More

Quick Read Stocks closed lower once again on Friday, handing investors their third consecutive week of losses. The “Buy the Dip” investors were rarely wrong using that tactic over the last 3 years, but have been scorched recently While it... Full story

Yahoo Finance • last month

Alnylam Tenaya Cardiovascular RNAi Pact And What It Means For Valuation

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Alnylam Pharmaceuticals (NasdaqGS:ALNY) has signed a multi year research collaboration with Tenaya... Full story

Yahoo Finance • last month

Tenaya Enters Research Collaboration With Alnylam; To Receive Up To $10 Mln In Upfront Payments

(RTTNews) - Tenaya Therapeutics (TNYA) announced a research collaboration agreement with Alnylam Pharmaceuticals (ALNY), to discover human genetic targets for the potential development of disease-modifying treatments for cardiovascular dis... Full story

Yahoo Finance • last month

Alnylam Receives Positive Recommendation From Canada's Drug Agency (CDA) for the Public Reimbursement of AMVUTTRA® (vutrisiran injection), the First and Only RNAi Therapeutic for the Treatment of Cardiomyopathy in Adult Patients with ATTR Amyloidosis

MISSISSAUGA, ON, March 2, 2026 /CNW/ - Alnylam Canada ULC is pleased to announce it has received a positive recommendation from Canada's Drug Agency (CDA) for the public reimbursement of its RNAi therapeutic, AMVUTTRA®.1 In December 2025,... Full story

Yahoo Finance • last month

Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major Players - Alnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics

Company Logo The oligonucleotides market offers opportunities in therapeutic applications, particularly for untreated diseases using ASOs, siRNA, and aptamers, with leaders like Alnylam driving innovation. Growth also spans diagnostics an... Full story

Yahoo Finance • last month

Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the 10 Unstoppable Stocks to Buy and Hold for the Next 3 Years.Canaccord Genuity Maintains Buy Rating on Alnylam Pharmaceuticals, Inc. (ALNY) Stock Alnylam Pharmaceuticals, Inc. (NASDAQ... Full story

Yahoo Finance • 2 months ago

Stock Market Today, Feb. 12: Stocks moderate as initial claims fall, continuing claims rise

This live blog is refreshed periodically throughout the day with the latest updates from the market.To find the latest Stock Market Today threads, click here. Happy Thursday. This is TheStreet’s Stock Market Today for Feb. 12, 2026. You c... Full story

Yahoo Finance • 2 months ago

Alnylam: Q4 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Alnylam Pharmaceuticals Inc. (ALNY) on Thursday reported fourth-quarter net income of $111.5 million, after reporting a loss in the same period a year earlier. On a per-share basis, the Camb... Full story

Yahoo Finance • 2 months ago

Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress

− Achieved Fourth Quarter and Full Year 2025 Global Net Product Revenues of $995 Million and $2,987 Million, Respectively, Representing 121% and 81% Growth Compared to Same Periods in 2024 – − Attained GAAP and non-GAAP Profitability for... Full story